ERLEADA® for Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

ERLEADA® is the FIRST AND ONLY AR inhibitor to report overall survival over ADT alone for patients with mCSPC in FDA-approved labeling

In the TITAN study in patients with mCSPC:

ERLEADA® + ADT reduced the risk of death by 33% vs placebo + ADT1

(Median overall survival was not estimable in either arm; HR=0.67; 95% CI: 0.51, 0.89; P=0.0053)

TITAN Primary Publication

Review the journal article to learn more about the study results

Accessing this article may require a subscription to The New England Journal of Medicine.


Exploratory Analysis:

TITAN Patient-Reported Outcomes Publication

Review the journal article to learn more about patient-reported outcomes in the TITAN study

Accessing this article may require a subscription to The Lancet Oncology.

ADT = androgen deprivation therapy; AR = androgen receptor; CI = confidence interval; FDA = US Food and Drug Administration; HR = hazard ratio; mCSPC = metastatic castration-sensitive prostate cancer; TITAN = Targeted Investigational Treatment Analysis of Novel Antiandrogen.

Reference

1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.